CD274 and urothelial carcinoma: Anti-PD-1/PD-L1 immunotherapy has achieved great progress in the treatment of certain cancers, such as melanoma [24], non-small cell lung cancer [25], urothelial carcinoma [26], renal cell carcinoma [27] and head and neck squamous cell carcinoma [28].